Meet Our Committees
Stewardship and Infection Prevention
Chair: Ebbing Lautenbach

The ARLG research agenda focuses on four high priority areas: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria (primarily MRSA and VRE), reducing the time to availability of antibiotic susceptibility data in serious bacterial infections, and stewardship of our remaining antibiotics.

Antibacterial exposure is a powerful selective pressure for emergence and spread of resistant organisms. Stewardship can reduce this pressure by limiting use of antibacterials, duration of use, and the spectrum of antibacterials that are used. As up to 50% of antibacterial use is inappropriate, strategies such as antibacterial restriction and prospective audits and feedback implemented at the institutional level can significantly reduce antibacterial use. Infection-prevention programs can reduce selective pressure by preventing the spread of organisms, both susceptible and resistant, and thus the need for antibacterial therapy. Our long-term objectives are to identify and develop institutional and provider-based strategies, approaches, and programs to reduce the use and environmental impact of antibacterials, and thus selective pressure for antibacterial resistance.

The Stewardship and Infection Prevention Committee is currently soliciting clinical studies to:

- Assess antibacterial stewardship strategies for non-use or early discontinuation of antibacterial therapy to reduce emergence and spread of antibiotic-resistant bacteria
- Evaluate transmission dynamics or emergence of carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant gram-negative bacilli in health care and community settings
- Examine strategies (e.g., stewardship, decolonization, probiotics) to prevent occurrence or recurrence or to reduce the risk of resistant gram-negatives, Clostridium difficile infection, VRE, or MRSA

Committee Member | Institution
--- | ---
Ebbing Lautenbach (Chair) | University of Pennsylvania
Deverick Anderson | Duke University
Scott Evans | Harvard University
Anthony Harris | University of Maryland
Timothy Jenkins | University of Colorado
Louis Rice | Brown University
Daniel Sexton | Duke University
Robert Weinstein | Rush University

For more information about the ARLG, its leaders, or its current projects, please visit arlg.org

The ARLG is featured in the recently released NIAID’s Antibacterial Resistance Research Program: Current Status and Future Directions which provides background information on current threats and NIAID programs.
ARLG Project Spotlight

**DICON1**

*A multicenter, 3-stage cluster randomized historically-controlled crossover trial to determine the feasibility and outcomes from two antimicrobial stewardship interventions in community hospitals.*

**Principal Investigator: Deverick Anderson**

The goal of DICON1 is to evaluate the feasibility of implementing formulary restriction and preauthorization versus prospective audit and feedback in resource-limited community hospitals.

To accomplish this, DICON1 has been designed as a 3-stage cluster, randomized, historically controlled, crossover trial in which one of two stewardship strategies, formulary restriction and preauthorization and post-antibiotic prescription review, will be utilized. The strategies will be deployed for patients hospitalized in one of the four participating community hospitals who receive one of the targeted or alternative antimicrobials.

Current ARLG Projects

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Principal Investigator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRIMERS</td>
<td><strong>Rapid gene detection of MDR GNB to direct and improve patient outcomes</strong></td>
<td>Robert Bonomo and Barry Kreiswirth</td>
</tr>
<tr>
<td>DICON1</td>
<td>A multicenter, 3-stage cluster randomized historically-controlled crossover trial to determine the feasibility and outcomes from two antimicrobial stewardship interventions in community hospitals</td>
<td>Deverick Anderson</td>
</tr>
<tr>
<td>NICU-AR</td>
<td>Data mining antibacterial resistance studies in NICU patients</td>
<td>Brian Smith</td>
</tr>
<tr>
<td>CRACKLE</td>
<td>Carbapenem-resistant Klebsiella pneumoniae in hospitalized patients</td>
<td>David van Duin</td>
</tr>
<tr>
<td>ZEST</td>
<td>A phase 2, multi-center, randomized, double-blind study to assess safety, tolerability and effectiveness of study drug in the treatment of patients with complicated UTIs</td>
<td>Brad Spellberg</td>
</tr>
<tr>
<td>BCID</td>
<td>Clinical and economic impact of rapid identification and susceptibility testing of pathogens growing in blood culture bottles</td>
<td>Ritu Banerjee</td>
</tr>
</tbody>
</table>

Recent Publications

